Symbiotec Pharmalab Ltd. IPO Details
Symbiotec Pharmalab was incorporated on September 20, 2002. The company is an R&D-driven, science-based pharmaceutical and biotechnology player with capabilities in organic chemistry, biotechnology, and complex injectables, and a global leadership position in corticosteroid and steroidal-hormone APIs. It is the only Indian and global company present across the top 10 such APIs in FY25, manufacturing them through fermentation and complex multi-step chemical processes
| Bidding Dates |
|---|
| 24 Aug 2026 - 27 Aug 2026 |
| Subscription |
|---|
| 1.85x Oversubscribed |
| Check Allotment Status |
|---|
| Minimum Investment | Minimum Lot | Maximum Lot | Lot Size | Number of Shares | Issue Price Band | Post Issue Promoter Holding % | Issue Size | IPO Document |
|---|---|---|---|---|---|---|---|---|
| ₹14,070 | 1 | 13 | 15 | 17.8 M | ₹938 - ₹988 | 33.28 % | ₹16680.8 M - ₹17570.0 M | RHP DOC |
Symbiotec Pharmalab IPO SUBSCRIPTION STATUS
25 Aug '26Symbiotec Pharmalab IPO overall subscription rate was 1.85 times the total available shares
Symbiotec Pharmalab IPO retail subscription rate was 2.1 times in the retail segment
Symbiotec Pharmalab IPO non-institutional investor subscription rate was 3 times in the non-institutional investor category
Symbiotec Pharmalab IPO Qualified Institutional Bidder subscription rate was 0.54 times the available shares for Qualified Institutional Bidder
Symbiotec Pharmalab IPO Employees subscription rate was 3.01 times in the Employees category
| Day | Retail Individual Investor | HNI (NII) Investors | Qualified Institutional Buyers | Employees |
|---|---|---|---|---|
| Category Reservation | 35% | 15% | 50% | - |
25 Aug 2026 (Day 2) | 2.1x | 3x | 0.54x | 3.01x |
24 Aug 2026 (Day 1) | 0.95x | 1.04x | 0.35x | 1.56x |
Symbiotec Pharmalab FINANCIALS
| Period | Revenue from Operations (Rs in crore) | Net Profit (Rs in crore) | Cash Flow from Operations (Rs in crore) | Free Cash Flow (Rs in crore) | Margins |
| Q1FY26 | 203.2 | 29.9 | 66.0 | 7.5 | 29.5% |
| FY25 | 751.6 | 96.8 | 47.3 | -260.9 | 27.3% |
| FY24 | 716.2 | 100.1 | 187.5 | -22.2 | 24.5% |
| FY23 | 566.5 | 23.5 | 69.2 | -155.1 | 13.0% |
Symbiotec Pharmalab IPO SUBSCRIPTION STATUS DETAILS
Symbiotec Pharmalab has 17.8 M shares on offer
Symbiotec Pharmalab IPO offer price is in the range ₹938 - ₹988
Symbiotec Pharmalab IPO minimum Investment is ₹14070
Symbiotec Pharmalab IPO issue size is ₹ 16680.8 M - ₹ 17570.0 M
Symbiotec Pharmalab has a minimum lot size of 15 Shares per application
Symbiotec Pharmalab NUMBER OF SHARES ON OFFER
Symbiotec Pharmalab IPO IMPORTANT DATES
| Issue Open Date | 24 Aug 2026 |
| Issue close Date | 27 Aug 2026 |
| Allotment Date | 28 Aug 2026 |
| Refund Date | 31 Aug 2026 |
| Demat Account Credit Date | 31 Aug 2026 |
| Listing Date | 01 Sep 2026 |
| Listing on Exchange(s) | NSE and BSE |
| Symbiotec Pharmalab Allotment Status | Exchange/ Registrar |
Symbiotec Pharmalab IPO subscription opens on 24 Aug 2026, and closes on 27 Aug 2026
IPO allotment for Symbiotec Pharmalab is expected to be finalized on Friday, 28 Aug 2026
IPO listing for Symbiotec Pharmalab will be on NSE and BSE on Tuesday, 01 Sep 2026
Symbiotec Pharmalab Peer
| Stock | Stock Price | Market Cap (Rs crore) | PE TTM | PEG TTM | PS TTM | ROE% | ROA% | Annual Revenue (Rs crore) | Annual Revenue Growth % | Annual Net Profit (Rs crore) | Annual Net Profit Growth % | EPS TTM | EPS TTM Growth % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Symbiotec Pharmalab Ltd. | 988 | 6348.2 | 57.8 | 4.3 | 7.3 | 9.6 | 6.2 | 872.3 | 15.4 | 109.9 | 13.5 | 17.1 | 13.5 |
| Sun Pharmaceutical Industries Ltd. | 1922 | 461152.2 | 38.1 | 2.3 | 7.7 | 13.7 | 10.6 | 60433.8 | 10.8 | 11479.4 | 5 | 50.4 | 16.6 |
| Divi's Laboratories Ltd. | 8744.5 | 232139 | 79.4 | 3 | 20.7 | 15.3 | 12.8 | 11067 | 14 | 2568 | 17.2 | 110.2 | 26.8 |
| Torrent Pharmaceuticals Ltd. | 4932 | 187597.4 | 86 | 9.6 | 11.9 | 25.8 | 4.9 | 13886.2 | 20.3 | 2163.4 | 13.2 | 57.3 | 8.9 |
| Cipla Ltd. | 1422 | 114876.7 | 34.1 | -0.9 | 4.1 | 11.3 | 9.1 | 29044.6 | 2.2 | 3879.2 | -26.4 | 41.7 | -37.5 |
| Zydus Lifesciences Ltd. | 1124.5 | 113151 | 25.1 | -16.2 | 4 | 18.6 | 9.6 | 27657.9 | 17.6 | 5040 | 11.4 | 44.9 | -1.6 |
Symbiotec Pharmalab INFORMATION ON IPO ISSUE
About Symbiotec Pharmalab
Symbiotec Pharmalab was incorporated on September 20, 2002. The company is an R&D-driven, science-based pharmaceutical and biotechnology player with capabilities in organic chemistry, biotechnology, and complex injectables, and a global leadership position in corticosteroid and steroidal-hormone APIs. It is the only Indian and global company present across the top 10 such APIs in FY25, manufacturing them through fermentation and complex multi-step chemical processes
Object of the Issue
- Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the company
- General corporate purposes
Symbiotec Pharmalab - PROMOTERS
| Name |
|---|
| Anil Satwani |
| Kashish Satwani |
| Sushil Satwani |
| Satwani Holdings LLP |
Symbiotec Pharmalab - MANAGEMENT & LEADERSHIP
| Name | Designation |
|---|---|
| Anil Satwani | Chairman & Managing Director |
| Rohit Mantri | Nominee Director |
| Hariharnath Buggana | Nominee Director |
| Sunita Kishnani | Non-Executive Independent Director |
| Pratik Patel | Non-Executive Independent Director |
| Richard Patrick Findlay Kenny | Non-Executive Independent Director |
Symbiotec Pharmalab Book Running Lead Manager
JM Financial Limited
symbiotec.ipo@jmfl.com
Avendus Capital Private Limited
symbiotec.ipo@avendus.com
Motilal Oswal Investment Advisors Limited
spl.ipo@motilaloswal.com
Nomura Financial Advisory and Securities (India) Private Limited
symbiotecipo@nomura.com
Symbiotec Pharmalab Registrar to the Offer
MUFG Intime India Private Limited
symbiotecpharmalab.ipo@in.mpms.mufg.com
Symbiotec Pharmalab Strengths
Client relationship
As of June 30, 2025, the company served over 200 customers across 40+ countries, including leading generic and specialty pharmaceutical companies, supported by strong quality assurance and consistent API supply. Its customer base has expanded steadily, with significant additions over the last three fiscals, strengthening its global commercial footprint
Multi-scale manufacturing platform
As of June 30, 2025, the company operated two API facilities and commissioned two additional plants, with significant capacities across chemical synthesis, fermentation, and complex injectables, while expanding biologics fermentation for GLP-1 and insulin demand. Its multi-scale fermenters enable flexible, high- and low-volume production and support CDMO services for fermentation-based products and complex injectables
R&D capabilities
The company’s innovation-driven, R&D-led approach has enabled it to build advanced capabilities in industrial-scale chemistry, fermentation, complex injectables, and drug–device combinations, evolving into a manufacturer with up to 400 cGMP-validated synthesis steps. Its differentiated pipeline, including in-house developed double-chamber devices and 505(b)(2) products, addresses large and growing global markets across APIs and specialty formulations
Symbiotec Pharmalab Risks
Compliance risks
The company’s manufacturing facilities are subject to regular regulatory and customer audits, and any quality or compliance failure could lead to regulatory action, reputational damage, and adverse impacts on operations and financial performance. Maintaining evolving certifications requires significant time, expertise, and investment, and is critical for market access and customer trust
Operational risks
The company’s operations involve hazardous materials and activities, which could lead to accidents, injuries, environmental damage, or legal liabilities, adversely impacting business, finances, and operations. Risks include fires, explosions, mechanical failures, natural disasters, and exposure to pollutants
Competition
The company operates in a highly competitive market, both in API manufacturing and as a newly established CDMO, and may be adversely affected if it cannot compete effectively. Competition comes from other pharmaceutical manufacturers and CDMO providers globally, with rivals investing heavily in product development and innovation
IPO FAQs
This IPO consists of an offer for sale of up to Rs 1,607.0 crore, of 16,265,182 shares. It also consists of a fresh issue of Rs 150.0 crore.
The promoters of the company are Anil Satwani, Kashish Satwani, Sushil Satwani and Satwani Holdings LLP.
The category allocation of qualified institutional buyers is 50.0%, the category allocation of non individual investors or high networth individuals is 15.0% and for retail investors it is 35.0%.
The price band of the IPO is Rs 938.0 - 988.0.
The IPO application opens on Aug 24, 2026 and closes on Aug 27, 2026.
The minimum lot size for the IPO is 15. The maximum lot size for the IPO is 195.
For all category investors, the minimum application amount for this IPO is Rs. 14,070.0, the maximum value for this IPO is Rs 192,660.0.
This IPO will be allotted on Aug 28, 2026.
The refund will be credited to your account on Aug 31, 2026.
The allotted shares will be credited to your demat on Aug 31, 2026.
Symbiotec Pharmalab Ltd.’s shares will list on the stock exchanges on Sep 01, 2026.